Cancer Blood Tests

Exact Sciences Stock Expands into Liquid Biopsy Market

Did you know that as early as the 1930s scientists were using wastewater – specifically, human excreta – to track disease outbreaks like polio well before the Rona came to town? Here’s another interesting scientific scoop on poop: One of the best treatments for people suffering from a serious bacterial gut infection is a fecal […]

Guardant Stock Plummets on Study Results

You know your consumer product is scaling when Katie Couric gives it a shout out. It’s even better when the product relates to something Ms. Couric feels very strongly about – colon cancer. Her husband died of colon cancer at the age of 42 in 1998. Several years later, Ms. Couric had a live colonoscopy […]

Is Freenome a Leading Cancer Blood-Testing Company?

The meltdown of the cryptocurrency exchange FTX is just the latest reminder that it can take time – and billions of dollars lost – to catch fraud, even when there are more red flags waving than in a Russian parade. For starters, any company flying its flag from the Bahamas should at least raise an […]

CareDx Stock is Pure Play on Organ Transplant Diagnostics

You know those pop TV shows that ask burning questions like, “Where are they now?” Usually, the episode will pick some child star who flamed out early, spending the better part of their youth burning through rerun royalties with drugs and alcohol. Today, little Johnny Boy is three years sober and doing a podcast interviewing […]

Why We No Longer Like Personalis Stock

As our tech investing methodology evolves, new rules help us better avoid risks and pitfalls by choosing companies that have proven their potential. Meaningful revenue of $10 million per year or more demonstrates traction, provided it’s not in the form of government grants. The larger the company, the more likely they’ll be able to raise […]

Guardant Health Stock: The Storm Before the Storm

Given today’s investor has such high expectations of growth it seems prudent to wait until after an earnings announcement before purchasing a stock. Likewise, checking in with a company right before earnings allows us to take an inventory of what’s happening prior to all the price action noise that typically takes place around earnings announcements. […]

What’s Up With Illumina’s Acquisition of GRAIL?

If you want to land a job at a top investment bank, there’s an expectation that you’ve read certain material. Even though prop trading desks have gone the way of the dodo, books like Liar’s Poker and Reminiscences of a Stock Operator are must-reads. So is the 592-page monster, Barbarians at the Gate, a glimpse […]

Why is Illumina’s Stock Price Falling?

Fewer than half of Americans own a passport. Some say that’s because their own backyard is such a big one. The half of our audience that hails from there may not be aware of what’s happening with global travel because they’re blissfully watching the stock market soar inexplicably. According to the World Tourism Barometer, international […]

Biodesix – A Lung Cancer Diagnostics Stock

One can’t help but wonder why the Americans are so worried about peanut allergies when 34 million of them use a product every day that slowly kills them. In the United States, cigarette smoking is linked to about 80% to 90% of lung cancer deaths. While we may not be able to pry someone’s cigarettes from their […]

Grail – A Pure-Play Stock For Cancer Blood Testing

Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an Initial Public Offering (IPO). Since we’re long Guardant (GH) given […]